Erratum to: Effects of Gefitinib, an Epidermal Growth Factor Receptor Inhibitor, on Human Placental Cell Growth:(Obstet Gynecol (2013) (122) (737–744)DOI: 10.1097/AOG.0b013e3182a1ba56);Effects of gefitinib, an epidermal growth factor receptor inhibitor, on human placental cell growth

Obstetrics and Gynecology

Volumn 122, Issue 4, 2013, Pages 737-744

  Nilsson, Ulrika W ^a,b,c,d,e   Johns, Terrance G ^a,b,c,d,e   Wilmann, Tania ^a,b,c,d,e   Kaitu'u Lino, Tu'uhevaha ^a,b,c,d,e   Whitehead, Clare ^a,b,c,d,e   Dimitriadis, Eva ^a,b,c,d,e   Menkhorst, Ellen ^a,b,c,d,e   Saglam, Burcu ^a,b,c,d,e   Gao, Yane ^a,b,c,d,e   Greenall, Sameer A ^a,b,c,d,e   Horne, Andrew W ^a,b,c,d,e   Tong, Stephen ^a,b,c,d,e  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b MONASH UNIVERSITY   (Australia)

^c HUDSON INSTITUTE OF MEDICAL RESEARCH   (Australia)

^d Xian Jiatong University School of Medicine   (China)

^e UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CHORIONIC GONADOTROPIN BETA SUBUNIT; EPIDERMAL GROWTH FACTOR RECEPTOR; GEFITINIB; METHOTREXATE;

ADULT; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CELL GROWTH; CELL TYPE; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; DRUG POTENCY; DRUG POTENTIATION; ECTOPIC PREGNANCY; EMBRYO; EXPERIMENTAL MODEL; FEMALE; FETUS RESORPTION; FIRST TRIMESTER PREGNANCY; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VIVO STUDY; MOUSE; NONHUMAN; PLACENTA; PLACENTA CELL; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; XENOGRAFT;

EID: 84889877211     PISSN: 00297844     EISSN: 1873233X     Source Type: Journal    
DOI: 10.1097/AOG.0000000000004380     Document Type: Erratum

References (20)

1. Centers for Disease Control and Prevention (CDC). Ectopic pregnancy-United States 1990-1992. MMWR Morb Mortal Wkly Rep 1995;44:46-8.
2. Lewis GE. Saving Mothers' Lives: reviewing maternal deaths to make motherhood safer-2003-2005. London (United Kingdom): The Confidential Enquiry into Maternal and Child Health (CEMACH); 2007.
3. Mol F, Mol BW, Ankum WM, van der Veen F, Hajenius PJ. Current evidence on surgery, systemic methotrexate and expectant management in the treatment of tubal ectopic pregnancy: A systematic review and meta-analysis. Hum Reprod Update 2008;14:309-19.
4. Herbst RS, Fukuoka M, Baselga J. Gefitinib- A novel targeted approach to treating cancer. Nat Rev Cancer 2004;4:956-65.
5. Su AI, Cooke MP, Ching KA, Hakak Y, Walker JR, Wiltshire T, et al. Large-scale analysis of the human and mouse transcriptomes. Proc Natl Acad Sci U S A 2002;99:4465-70.
6. Wu C, Orozco C, Boyer J, Leglise M, Goodale J, Batalov S, et al. BioGPS: An extensible and customizable portal for querying and organizing gene annotation resources. Genome Biol 2009;10:R130.
7. LaMarca HL, Dash PR, Vishnuthevan K, Harvey E, Sullivan DE, Morris CA, et al. Epidermal growth factor-stimulated extravillous cytotrophoblast motility is mediated by the activation of PI3-K, Akt and both p38 and p42/44 mitogen-activated protein kinases. Hum Reprod 2008;23:1733-41.
8. Johnstone ED, Mackova M, Das S, Payne SG, Lowen B, Sibley CP, et al. Multiple anti-apoptotic pathways stimulated by EGF in cytotrophoblasts. Placenta 2005;26:548-55.
9. Wolff GS, Chiang PJ, Smith SM, Romero R, Armant DR. Epidermal growth factor-like growth factors prevent apoptosis of alcohol-exposed human placental cytotrophoblast cells. Biol Reprod 2007;77:53-60.
10. Sibilia M, Wagner EF. Strain-dependent epithelial defects in mice lacking the EGF receptor. Science 1995;269:234-8.
11. Cohen MH, Williams GA, Sridhara R, Chen G, McGuinn WD Jr, Morse D, et al. United States Food and Drug Administration Drug Approval summary: Gefitinib (ZD1839; Iressa) tablets. Clin Cancer Res 2004;10:1212-8.
12. Ciardiello F, Tortora G. EGFR antagonists in cancer treatment. N Engl J Med 2008;358:1160-74.
13. Cartwright JE, Kenny LC, Dash PR, Crocker IP, Aplin JD, Baker PN, et al. Trophoblast invasion of spiral arteries: A novel in vitro model. Placenta 2002;23:232-5.
14. Paiva P, Salamonsen LA, Manuelpillai U, Walker C, Tapia A, Wallace EM, et al. Interleukin-11 promotes migration, but not proliferation, of human trophoblast cells, implying a role in placentation. Endocrinology 2007;148:5566-72.
15. Kaitu'u-Lino TJ, Pattison S, Ye L, Tuohey L, Sluka P, MacDiarmid J, et al. Targeted nanoparticle delivery of doxorubicin into placental tissues to treat ectopic pregnancies. Endocrinology 2013;154:911-9.
16. Ferretti C, Bruni L, Dangles-Marie V, Pecking AP, Bellet D. Molecular circuits shared by placental and cancer cells, and their implications in the proliferative, invasive and migratory capacities of trophoblasts. Hum Reprod Update 2007;13: 121-41.
17. Dutta PR, Maity A. Cellular responses to EGFR inhibitors and their relevance to cancer therapy. Cancer Lett 2007; 254:165-77.
18. Ciardiello F, Caputo R, Bianco R, Damiano V, Pomatico G, De Placido S, et al. Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor. Clin Cancer Res 2000;6:2053-63.
19. Jurkovic D, Wilkinson H. Diagnosis and management of ectopic pregnancy. BMJ 2011;342:d3397.
20. Skubisz MM, Horne AW, Johns TG, Nilsson UW, Duncan WC, Wallace EM, et al. Combination gefitinib and methotrexate compared with methotrexate alone to treat ectopic pregnancy. Obstet Gynecol 2013:122:745-51.